Glyconix

GlycoNex is a clinical-stage biotechnology company based in Taiwan that specializes in the development of glycan-targeted monoclonal antibodies for the treatment of various cancers. The company utilizes its proprietary platform to identify tumor-associated carbohydrate antigens (TACAs), such as SSEA-4 and Globo H, which are highly expressed on the surface of malignant cells but have limited expression in normal tissues. Its lead therapeutic candidate, GNX-102, is a humanized monoclonal antibody targeting SSEA-4 and is currently being evaluated in Phase 2 clinical trials for solid tumors, including gastric and lung cancers. Beyond its lead program, GlycoNex is advancing a pipeline of next-generation therapies, including antibody-drug conjugates (ADCs) and bispecific antibodies, aimed at improving outcomes for patients with difficult-to-treat malignancies. The company maintains a global presence with clinical operations in both Taiwan and the United States.